secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0001104659-22-057216
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco Q1 revenue $1.225B, adj. EPS $0.36; FY22 guidance lowered on FX headwind of $140M
--------------------------------------------------------------------------------

- Q1 revenue $1,225M (-1% reported, +2% CER); reported net income $48M vs -$61M; adjusted EPS $0.36 vs $0.37.
- FY22 revenue guidance cut to $4,700-4,755M from $4,745-4,800M due to incremental $45M FX headwind; adj. EPS guidance $1.15-1.21.
- Strategic alliance with Royal DSM for exclusive U.S. rights to Bovaer methane-reducing feed additive; >$200M annual revenue potential.
- Pet Health revenue $639M; Seresto grew 6% to $161M; Advantage declined 5% to $137M, with temporary U.S. stock-outs.
- Completed $406M tender on 4.272% Senior Notes due 2023; new $250M term facility with Farm Credit; net leverage 5.6x.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000110465922057216/0001104659-22-057216-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000110465922057216/tm2214854d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-057216

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer